Primecap Management Co. CA Makes New Investment in Palvella Therapeutics, Inc. $PVLAMarket Beat·Aug 27 at 09:23 AMPVLA+1.14%LGEN
Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chatPUBT·Aug 5 at 11:30 AMPVLA+1.14%
Palvella Q2 2026 earnings: R&D spending widens loss as NDA advancesTradingKey·Aug 5 at 07:14 AMPVLA+1.14%
High-Risk Warning for Investors in Palvella Therapeutics SecuritiesTip Ranks·Aug 5 at 06:02 AMPVLA+1.14%
PVLA: Positive phase III data, rolling NDA, and strong cash position drive launch readiness and pipeline growthQuartr·Aug 4 at 02:51 PMPVLA+1.14%
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Callbenzinga_article·Aug 4 at 01:52 PMPVLA+1.14%
PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9MQuartr·Aug 4 at 12:08 PMPVLA+1.14%
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateUnusual Whales·Aug 4 at 11:35 AMPVLA+1.14%
Palvella net loss widens 130.88% to $21.87 million in Q2 FY26; R&D expenses more than doubled to $12.47 millionPUBT·Aug 4 at 11:32 AMPVLA+1.14%
Chardan Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-BuyMarket Beat·Jul 31 at 11:06 AMPVLA+1.14%
Palvella Therapeutics CSO Jeff Martini presents at FDA drug repurposing workshopPUBT·Jul 30 at 11:46 AMPVLA+1.14%
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026Unusual Whales·Jul 28 at 11:33 AMPVLA+1.14%
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filingrttnews·Jul 22 at 03:25 AMASBP-4.11%DYAI+3.89%
